Summary of clinical characteristics of healthy controls and patients with myeloid malignancies
| Characteristic . | Myeloid patients (N = 48) . | Healthy controls (N = 16) . |
|---|---|---|
| Median age (range), y | 70 (28-89) | 34.5 (21-75) |
| Sex | 27 males/21 females | 5 males/11 females |
| Diagnosis | ||
| MDS | N = 23 | |
| AML | N = 13 | |
| CMML | N = 1 | |
| Jak2V617F+ MPN | ||
| ET | N = 1 | |
| PV | N = 6 | |
| MF | N = 4 | |
| Treatment | ||
| Observation/growth factors | N = 16 | |
| HMA (azacitidine or decitabine) monotherapy | N = 7 | |
| HMA/venetoclax | N = 10 | |
| HMA/other | N = 4 | |
| Allo-BMT | N = 2 | |
| Peginterferon | N = 1 | |
| Hydroxyurea | N = 3 | |
| Ruxolitinib | N = 3 | |
| Ruxolitinib/hydroxyurea | N = 1 | |
| Anagrelide | N = 1 | |
| Vaccines/boosters | ||
| Moderna (second vaccine) | N = 19 | N = 8 |
| Pfizer (second vaccine) | N = 18 | N = 8 |
| Janssen (1 vaccine) | N = 1 | |
| Same mRNA second and third vaccines | N = 9 | N = 8 |
| Mixed mRNA second and third vaccines (Moderna-Pfizer) | N = 1 | N = 8 |
| Documented breakthrough SARS-CoV-2 infection | N = 3 | |
| Median time of sample collection from second vaccine dose | 150.5 d | 38 d |
| Median time of sample collection from third vaccine dose | 30.5 d | 57.5 d |
| Characteristic . | Myeloid patients (N = 48) . | Healthy controls (N = 16) . |
|---|---|---|
| Median age (range), y | 70 (28-89) | 34.5 (21-75) |
| Sex | 27 males/21 females | 5 males/11 females |
| Diagnosis | ||
| MDS | N = 23 | |
| AML | N = 13 | |
| CMML | N = 1 | |
| Jak2V617F+ MPN | ||
| ET | N = 1 | |
| PV | N = 6 | |
| MF | N = 4 | |
| Treatment | ||
| Observation/growth factors | N = 16 | |
| HMA (azacitidine or decitabine) monotherapy | N = 7 | |
| HMA/venetoclax | N = 10 | |
| HMA/other | N = 4 | |
| Allo-BMT | N = 2 | |
| Peginterferon | N = 1 | |
| Hydroxyurea | N = 3 | |
| Ruxolitinib | N = 3 | |
| Ruxolitinib/hydroxyurea | N = 1 | |
| Anagrelide | N = 1 | |
| Vaccines/boosters | ||
| Moderna (second vaccine) | N = 19 | N = 8 |
| Pfizer (second vaccine) | N = 18 | N = 8 |
| Janssen (1 vaccine) | N = 1 | |
| Same mRNA second and third vaccines | N = 9 | N = 8 |
| Mixed mRNA second and third vaccines (Moderna-Pfizer) | N = 1 | N = 8 |
| Documented breakthrough SARS-CoV-2 infection | N = 3 | |
| Median time of sample collection from second vaccine dose | 150.5 d | 38 d |
| Median time of sample collection from third vaccine dose | 30.5 d | 57.5 d |
AML, acute myeloid leukemia; BMT, bone marrow transplant; CMML, chronic myelomonocytic leukemia; ET, essential thrombocytopenia; HMA, hypomethylating agent; MF, myelofibrosis; PV, polycythemia vera.